Covered recipient · General Payments record
MARK D LAURON
Allopathic & Osteopathic Physicians Internal Medicine
General Payments · PY2018–2024
$4,393.25
- Reported across 173 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $640.52 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Abbott Laboratories | $288.00 | 8 |
| Novo Nordisk AS | $161.96 | 5 |
| Acerta Pharma LLC | $135.48 | 2 |
| GlaxoSmithKline, LLC. | $32.30 | 1 |
| Amgen Inc. | $22.78 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $19.49 | 03/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125343001 | CMS |
| Abbott Laboratories | $2.11 | 05/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125343003 | CMS |
| Abbott Laboratories | $29.85 | 05/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125343005 | CMS |
| Abbott Laboratories | $24.02 | 06/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125343007 | CMS |
| Abbott Laboratories | $24.24 | 08/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125343009 | CMS |
| Abbott Laboratories | $140.63 | 10/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125343011 | CMS |
| Abbott Laboratories | $24.49 | 11/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125343013 | CMS |
| Abbott Laboratories | $23.17 | 11/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125343015 | CMS |
| Amgen Inc. | $22.78 | 05/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117306340 | CMS |
| AstraZeneca Pharmaceuticals LP | $117.18 | 01/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105833009 | CMS |
| AstraZeneca Pharmaceuticals LP | $18.30 | 09/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104646513 | CMS |
| GlaxoSmithKline, LLC. | $32.30 | 11/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116702717 | CMS |
| Novo Nordisk Inc | $12.32 | 02/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097184729 | CMS |
| Novo Nordisk Inc | $90.09 | 06/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097613958 | CMS |
| Novo Nordisk Inc | $21.25 | 06/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097702214 | CMS |
| Novo Nordisk Inc | $20.80 | 07/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097708921 | CMS |
| Novo Nordisk Inc | $17.50 | 10/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097633501 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.